IN THE NEWS
-
INTEGRAGEN UPDATE - ALWAYS OPEN FOR YOUR PROJECTS
IntegraGen follows government recommendations and precautionary measures related to the COVID-19 crisis. As a leading provider of genomic services, we are committed to... Read More
-
INTEGRAGEN - ANNUAL RESULTS 2019
Sales growth (+201TP3Q), positive EBITDA in the second half and close to breakeven for the full year IntegraGen today announced its financial results for the year ended... Read More
-
INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL
IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, in their analysis and reporting of tumor sequencing data... Read More
LATEST NEWS
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that the... Read More
-
INTEGRAGEN NOMINATED FOR THE GALIEN MEDSTARTUP AWARD 2018
IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the... Read More
-
GOPATH LABORATORIES ANNOUNCE THE LAUNCH OF THE MIR-31NOW TEST
GoPath Laboratories today announced the launch of a new proprietary test, miR31nowTM, to coincide with... Read More
-
INTEGRAGEN PARTICIPATES IN THE ASCO 2018 AMERICAN CANCER CONGRESS HELD IN CHICAGO FROM JUNE 1 TO 5
The annual ASCO meeting brings together more than 32,000 cancer specialists from around the world to... Read More
